Nick Cetateanu
Chief Operating Officer at Purespring Therapeutics Ltd.
Network origin in Nick Cetateanu first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom.
4
| Holding Company | Miscellaneous Commercial Services | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Nick Cetateanu via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Executive Officer Private Equity Investor | |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| Forcefield Therapeutics Ltd. | Chairman Chief Executive Officer | ||
Apposite Capital LLP
 Apposite Capital LLP Investment ManagersFinance Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
| Syncona Ip Holdco Ltd. | Director/Board Member | ||
Novasep Holding SAS
 Novasep Holding SAS Chemicals: Major DiversifiedProcess Industries Novasep Holding SAS provides manufacturing solutions for the life science industries. Its products include agrochemicals fine chemicals and food ingredients. The company was founded by Roger-Marc Nicoud in 1995 and is headquartered in Lyon, France. | Chemicals: Major Diversified | Director/Board Member | |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Pharmaceuticals: Generic | Chief Executive Officer | |
Mettler-Toledo (Schweiz) GmbH
 Mettler-Toledo (Schweiz) GmbH Industrial MachineryProducer Manufacturing Mettler-Toledo (Schweiz) GmbH manufactures measurement solutions and precision instruments. The firm offers laboratory weighing scales, industrial scales and load cell systems, inline product quality inspection products, rainin pipettes and tips, process analytics, truck scales/weighbridges and dimensioning, analytical instruments, automated reactors and in situ analysis, retail weighing scales, and transport and logistics solutions. The company is headquartered in Greifensee, Switzerland. | Industrial Machinery | Director/Board Member | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Manchester Metropolitan University | College/University | Undergraduate Degree | |
| METTLER-TOLEDO INTERNATIONAL, INC. | Medical Specialties | Director/Board Member | |
Sandoz International GmbH
 Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Sandoz International GmbH develops and manufactures generic pharmaceuticals. It produces finished dosage forms of such off-patent drugs as diabetes treatment Glucophage, GERD drug Prilosec, and cholesterol. The company was founded in 1996 and is headquartered in Holzkirchen, Austria. | Pharmaceuticals: Generic | Chief Executive Officer | |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Pharmaceuticals: Generic | Director/Board Member | |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Biotechnology | Chairman | |
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chairman | |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Director/Board Member | |
| FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chairman | |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Chairman | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| NIGHTSTAR THERAPEUTICS PLC | Pharmaceuticals: Major | Chairman | |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Founder | |
| University of Cambridge | College/University | Doctorate Degree | |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| Imperial College London | College/University | Doctorate Degree |
Statistics
International
| United Kingdom | 17 |
| United States | 6 |
| France | 2 |
| Israel | 2 |
| Switzerland | 2 |
Sectoral
| Health Technology | 15 |
| Consumer Services | 4 |
| Finance | 3 |
| Health Services | 2 |
| Process Industries | 2 |
Operational
| Director/Board Member | 15 |
| Chairman | 8 |
| Chief Executive Officer | 6 |
| Independent Dir/Board Member | 3 |
| Corporate Officer/Principal | 3 |
Most connected contacts
| Insiders | |
|---|---|
| Chris Hollowood | 18 |
| Richard Francis | 8 |
| Julian Hanak | 3 |
| Michael Kyriakides | 3 |
- Stock Market
- Insiders
- Nick Cetateanu
- Company connections
